CVS brings Tigi Cosmetics to 2,000 stores

Print Friendly, PDF & Email

WOONSOCKET, R.I. — CVS Pharmacy has continued its rollout of premium and niche beauty brands with the introduction this month of some 60 products from Tigi Cosmetics at 2,000 CVS drug stores and on the CVS.com website.

In addition, Tigi’s assortment will get high-visibility placement on the retailer’s “trend wall,” an innovation introduced this year as a means of featuring hot new brands and products.­

Tigi Cosmetics will continue catering to the professional beauty community by distributing its products to salons and offer them online. This month’s launch at CVS marks the first time the premium brand is available for purchase at a major national retailer, Tigi ­commented.

The cosmetics that Tigi is supplying to CVS were developed and specially curated to help customers “achieve a flawless complexion and experiment with color,” according to the Coppell, Texas-based company.

For CVS, the Tigi products represent its latest penetration into on-trend brands, which in 2017 has included Wunder2, Vinylux and Mineral Fusion. These follow a slew of additions last year. Many of the new products and brands are exclusive to CVS.

“CVS Pharmacy has a prestigious position within the beauty industry and continues to turn heads with their ever-growing selection of product offerings,” explained Hazel Smith, brand manager at Tigi Cosmetics. “We are excited to tie our brand name to such a phenomenal partner and look forward to continued success.”

Products include the following: Diamond Lipsticks ($26 suggested retail price), which feature an angled shape for precise application and are infused with vitamin E and rose hip seed oil to condition lips all day long; Perfect Eyeliners ($21), with a creamy formula that goes on smooth and includes a smudgy tip for a smoky eye look; and High Definition Setting Powder ($38), which includes micro-pigments that help blur out fine lines and pores while mattifying skin for a smooth, soft-focus finish, the company noted.



Comments are closed.